EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Review article: Translating STRIDE‐II into clinical reality – Opportunities and challenges

Axel Dignass iD, Stefan Rath iD, Thomas Kleindienst, Andreas Stallmach iD

Alimentary Pharmacology & Therapeutics · 2023-09 · 58 (5) · 492-502

DOI: 10.1111/apt.17622 ↗

At a glance

Übersichtsarbeit in Alimentary Pharmacology & Therapeutics, published online on 2023-06-29. Written by Axel Dignass and 3 co-authors. Institution: Department of Medicine I, Agaplesion Markus Hospital, Frankfurt/Main, Germany. Major MEDLINE topics: Inflammatory Bowel Diseases, Colitis, Ulcerative. Cited 43 times so far (Crossref); 58 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: AbbVie.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

With the introduction of novel therapies for inflammatory bowel diseases (IBD), ‘treat‐to‐target’ strategies are increasingly discussed to improve short‐ and long‐term outcomes in patients with IBD.

Aim

To discuss opportunities and challenges of a treat‐to‐target approach in light of the current ‘Selecting Therapeutic Targets in Inflammatory Bowel Disease’ (STRIDE‐II) consensus Methods The 2021 update of STRIDE‐II encompasses 13 evidence‐ and consensus‐based recommendations for treat‐to‐target strategies in adults and children with IBD. We highlight the potential implications and limitations of these recommendations for clinical practice.

Results

STRIDE‐II provides valuable guidance for personalised IBD management. It reflects scientific progress as well as increased evidence of improved outcomes when more ambitious treatment goals such as mucosal healing are achieved.

Conclusions

Prospective studies, objective criteria for risk stratification, and better predictors of therapeutic response are needed to potentially render ‘treating to target’ more effective in the future.

Subjects

MeSH terms (MEDLINE)

Inflammatory Bowel DiseasesColitis, UlcerativeChildAdultHumansProspective StudiesForecastingWound Healing

Author keywords

Crohn’s disease < disease-basedbiologics (IBD) < topicsinflammatory bowel disease < disease-basedulcerative colitis < disease-based

Authors and institutions

  • Department of Medicine I, Agaplesion Markus Hospital, Frankfurt/Main, Germany.
  • Department of Medical Immunology, AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.
  • Department of Internal Medicine IV, University Hospital Jena, Jena, Germany.

ORCID profiles: Axel Dignass, Stefan Rath, Andreas Stallmach

Funding

  • AbbVie

Cite

APA

Dignass, A., Rath, S., Kleindienst, T., & Stallmach, A. (2023). Review article: Translating STRIDE‐II into clinical reality – Opportunities and challenges. Alimentary Pharmacology & Therapeutics, 58(5), 492-502. https://doi.org/10.1111/apt.17622

Vancouver

Dignass A, Rath S, Kleindienst T, Stallmach A. Review article: Translating STRIDE‐II into clinical reality – Opportunities and challenges. Alimentary Pharmacology & Therapeutics. 2023;58(5):492-502. doi:10.1111/apt.17622

BibTeX
@article{Dignass2023,
  author = {Dignass, Axel and Rath, Stefan and Kleindienst, Thomas and Stallmach, Andreas},
  title = {Review article: Translating STRIDE‐II into clinical reality – Opportunities and challenges},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  volume = {58},
  number = {5},
  pages = {492--502},
  doi = {10.1111/apt.17622}
}
Start for free →